scispace - formally typeset
Search or ask a question
Institution

University of Alabama at Birmingham

EducationBirmingham, Alabama, United States
About: University of Alabama at Birmingham is a education organization based out in Birmingham, Alabama, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 38523 authors who have published 86775 publications receiving 3930642 citations. The organization is also known as: UAB & The University of Alabama at Birmingham.


Papers
More filters
Journal ArticleDOI
TL;DR: The importance of matrix-producing organisms in fostering a pathogenic habitat where interspecies competition and synergies occur to drive the disease process is highlighted, which could have implications to other infections associated with polymicrobial biofilms.

518 citations

Journal ArticleDOI
TL;DR: In this trial of the initial treatment of HIV-1 infection, the triple-nucleoside combination of abacavir, zidovudine, and lamivudine was virologically inferior to a regimen containing efavirenz and two or three nucleosides.
Abstract: Background Regimens containing three nucleoside reverse-transcriptase inhibitors offer an alternative to regimens containing nonnucleoside reverse-transcriptase inhibitors or protease inhibitors for the initial treatment of human immunodeficiency virus type 1 (HIV-1) infection, but data from direct comparisons are limited. Methods This randomized, double-blind study involved three antiretroviral regimens for the initial treatment of subjects infected with HIV-1: zidovudine–lamivudine–abacavir, zidovudine–lamivudine plus efavirenz, and zidovudine–lamivudine–abacavir plus efavirenz. REsults We enrolled a total of 1147 subjects with a mean baseline HIV-1 RNA level of 4.85 log10 (71,434) copies per milliliter and a mean CD4 cell count of 238 per cubic millimeter were enrolled. A scheduled review by the data and safety monitoring board with the use of prespecified stopping boundaries led to a recommendation to stop the triple-nucleoside group and to present the results in the triple-nucleoside group in compari...

518 citations

Journal ArticleDOI
TL;DR: PHEN/TPM CR in conjunction with lifestyle modification may provide a well-tolerated and effective option for the sustained treatment of obesity complicated by cardiometabolic disease.

517 citations

Journal ArticleDOI
01 Feb 2012-Obesity
TL;DR: PHEN/TPM CR demonstrated dose‐dependent effects on weight and metabolic variables in the direction expected to be beneficial with no evidence of serious adverse events induced by treatment.
Abstract: A 56-week randomized controlled trial was conducted to evaluate safety and efficacy of a controlled-release combination of phentermine and topiramate (PHEN/TPM CR) for weight loss (WL) and metabolic improvements. Men and women with class II and III obesity (BMI ≥ 35 kg/m2) were randomized to placebo, PHEN/TPM CR 3.75/23 mg, or PHEN/TPM CR 15/92 mg, added to a reduced-energy diet. Primary end points were percent WL and proportions of patients achieving 5% WL. Secondary end points included waist circumference (WC), systolic and diastolic blood pressure (BP), fasting glucose, and lipid measures. In the primary analysis (randomized patients with at least one postbaseline weight measurement who took at least one dose of assigned drug or placebo), patients in the placebo, 3.75/23, and 15/92 groups lost 1.6%, 5.1%, and 10.9% of baseline body weight (BW), respectively, at 56 weeks (P < 0.0001). In categorical analysis, 17.3% of placebo patients, 44.9% of 3.75/23 patients, and 66.7% of 15/92 patients, lost at least 5% of baseline BW at 56 weeks (P < 0.0001). The 15/92 group had significantly greater changes relative to placebo for WC, systolic and diastolic BP, fasting glucose, triglycerides, total cholesterol, low-density lipoprotein (LDL), and high-density lipoprotein (HDL). The most common adverse events were paresthesia, dry mouth, constipation, dysgeusia, and insomnia. Dropout rate from the study was 47.1% for placebo patients, 39.0% for 3.75/23 patients, and 33.6% of 15/92 patients. PHEN/TPM CR demonstrated dose-dependent effects on weight and metabolic variables in the direction expected to be beneficial with no evidence of serious adverse events induced by treatment.

517 citations

Journal ArticleDOI
22 Dec 2000-Science
TL;DR: Evidence for allele-specific association between the putative disease locus and marker D10S583, which has recently been located within 195 kilobases of the IDE gene, is found.
Abstract: Recent studies suggest that insulin-degrading enzyme (IDE) in neurons and microglia degrades Abeta, the principal component of beta-amyloid and one of the neuropathological hallmarks of Alzheimer's disease (AD). We performed parametric and nonparametric linkage analyses of seven genetic markers on chromosome 10q, six of which map near the IDE gene, in 435 multiplex AD families. These analyses revealed significant evidence of linkage for adjacent markers (D10S1671, D10S583, D10S1710, and D10S566), which was most pronounced in late-onset families. Furthermore, we found evidence for allele-specific association between the putative disease locus and marker D10S583, which has recently been located within 195 kilobases of the IDE gene.

516 citations


Authors

Showing all 38940 results

NameH-indexPapersCitations
Rudolf Jaenisch206606178436
Joel Schwartz1831149109985
Tadamitsu Kishimoto1811067130860
Jasvinder A. Singh1762382223370
Gregg L. Semenza168502130316
David R. Jacobs1651262113892
Hua Zhang1631503116769
David R. Holmes1611624114187
David Cella1561258106402
Elaine S. Jaffe156828112412
Michael A. Matthay15199898687
Lawrence Corey14677378105
Barton F. Haynes14491179014
Douglas D. Richman14263382806
Kjell Fuxe142147989846
Network Information
Related Institutions (5)
University of Pittsburgh
201K papers, 9.6M citations

98% related

University of California, San Francisco
186.2K papers, 12M citations

98% related

National Institutes of Health
297.8K papers, 21.3M citations

97% related

Brigham and Women's Hospital
110.5K papers, 6.8M citations

97% related

University of North Carolina at Chapel Hill
185.3K papers, 9.9M citations

97% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
2023168
2022530
20215,327
20205,028
20194,402
20184,083